KAI1/CD82与C-erbB-2在乳腺癌中的表达及其临床意义  

Expression of KAI1/CD82 and C-erbB-2 in breast cancer and its clinical significance

作　　者：赵云霞[1] 赵瑾[1] 刘德纯[2] 承泽农[2] 

机构地区：[1]蚌埠医学院病理生理学教研室,安徽蚌埠233030 [2]蚌埠医学院病理学教研室,安徽蚌埠233030

出　　处：《蚌埠医学院学报》2011年第10期1058-1060,1063,共4页Journal of Bengbu Medical College

基　　金：安徽省教育厅自然科学研究资助项目(KJ2010B122);蚌埠医学院科研资助项目(BY0737)

摘　　要：目的:探讨KAI1/CD82及C-erbB-2在乳腺癌中的表达及其临床意义。方法:采用免疫组织化学S-P法检测57例乳腺癌组织和11例乳腺良性病变组织中KAI1/CD82及C-erbB-2的表达,分析其与临床病理参数的关系。结果:57例乳腺癌组织和11例乳腺良性病变组织中KAI1/CD82、C-erbB-2阳性率分别为31.58%和81.82%、71.93%和0.00%,差异均有统计学意义(P<0.01)。乳腺癌患者中,淋巴结未转移、雌激素受体(ER)阴性者的KAI1/CD82阳性率高于淋巴结转移、ER阳性者(P<0.05);ER阳性患者C-erbB-2的阳性率低于ER阴性者(P<0.05)。KAI1/CD82与C-erbB-2在乳腺癌中的表达无相关关系(P>0.05)。结论:KAI1/CD82和C-erbB-2均参与了乳腺癌的发生、发展过程,对乳腺癌的浸润和转移及预后评估具有临床参考意义。Objective：To explore the expression of KAI1/CD82 and C-erbB-2 in breast cancer and its clinieal significance.Methods：The expression of KAI1/CD82,C-erbB-2 and estrogen receptor（ER） in 57 cases of breast cancer and 11 cases of benign mammary lesions were detected by immunohistochemistry S-P method,and their correlation with the clinicopathologic features was analyzed.Results：The positive rate of KAI1/CD82 was 31.58% in the breast cancer and 81.82% in the benign mammary lesions.The positive rate of C-erbB-2 was 71.93% in the breast cancer and zero in benign mammary lesions.The difference was statistically significant between the two groups（P0.01）.The positive expression of KAI1/CD82 had statistical difference in cases with no metastasis of auxiliary lymph nodes and cases with negative expression of ER（P0.05）.The positive expression of C-erbB-2 in cases with positive expression of ER was lower than that in cases with negative expression of ER（P0.05）.The expression of KAI1/CD82 and C-erbB-2 in breast cancer had no correlation.Conclusions：KAI1/CD82 and C-erbB-2 both participate in the proceeding of breast cancer,they may help to evaluate the invasiveness and metastasis of breast cancer.

关 键 词：乳腺肿瘤 KAI1/CD82 C-ERBB-2 免疫组织化学 

分 类 号：R737.9[医药卫生—肿瘤]